Colonic bacterial composition in Parkinson's disease

By Ali Keshavarzian, S. Green, P. Engen, Robin M. Voigt, A. Naqib, C. Forsyth, E. Mutlu, K. Shannon. Movement Disorders, 2015

1,138 citations recorded by the source corpus.

Subfields: Gastroenterology, Molecular Biology, Neurology

View Paper: https://www.semanticscholar.org/paper/67738b53e09a021e196eed9121d4ce179acd62e5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Gastroenterology

In Molecular Biology

In Neurology

Daniel H. Geschwind

Citations in the corpus

Parkinson’s Disease and PD Medications Have Distinct Signatures of the Gut Microbiome (2017, background): “Several studies have implicated depletion of short chain fatty acids (SCFA) in the pathogenesis of PD.10,12,14,35-37 SCFA is made by bacteria in the gut, notably Lachnospiraceae.”
Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. (2018, result): “Another study also demonstrated that the colonic bacterial phylum Bacteroidetes and the bacterial family Prevotellaceaewere reduced while Enterobacteriaceae were more abundant in PD patients (Keshavarzian et al., 2015).”
Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. (2017, background): “Two interesting studies (Keshavarzian et al., 2015; Hasegawa et al., 2015) provide evidence that pro-inflammatory dysbiosis could trigger inflammation-induced misfolding of α -synuclein the development of PD.”
The Central Nervous System and the Gut Microbiome (2016, background): “Concurrently, individuals afflicted with Parkinson’s disease (PD) display significantly different fecal and mucosal microbial populations (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015).”
Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease (2016, neutral): “Conversely, the gut microbiomes in human subjects with PD contain an increased abundance of Proteobacteria (Hasegawa et al., 2015; Keshavarzian et al., 2015; Scheperjans et al., 2015; Unger et al., 2016), remarkably similar to our results in mice.”
Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration (2017, neutral): “This was coincident with an increase in Ralstonia in mucosal samples more abundant in mucosa of PD than controls (Keshavarzian et al. 2015).”
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis (2019, background): “samples and sigmoid mucosal biopsies from patients with PD, corresponding to the inflammation-related misfolding of α-synuclein and pathology of PD in CNS [163].”
Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. (2016, background): “Concerning the effect of medication on microbiota, we identified a strong negative correlation between the use of entacapone and the abundance of Firmicutes and Faecalibacterium prausnitzii.”